INTRODUCTION
The anatomical identity of mesenchymal stem/stromal cells (''MSCs,'' the current ''jargon''), their phenotype, distribution in different tissues, lineage, physiological functions, and biological properties represent one of the most controversial and confusing areas in stem cell biology. At this time, two quite distinct descriptions of ''MSCs'' are found in the literature. One, which emanates from $50 years of widely reproduced experimental work in vivo, sees ''MSCs'' as the same biological object previously known as cultured bone marrow stromal cells (BMSCs); these cells are unique to bone marrow (BM), and include a subset of physically identifiable clonogenic, multipotent, self-renewing progenitors of skeletal tissues, and skeletal tissues only (Bianco et al., 2013) . This progenitor is endowed with the unique capacity to organize the hematopoietic microenvironment and the hematopoietic stem cell niche (Bianco, 2011; Friedenstein et al., 1982) . The other view sees ''MSCs'' as progenitors of multiple tissues beyond the range of skeletal tissues, such as skeletal muscle (Caplan, 1991 (Caplan, , 2008 Crisan et al., 2008) . The demonstration that ''MSCs'' are perivascular cells in BM was later extrapolated to claim that in virtually all tissues, pericytes (identified as CD34 À /CD45 À /CD146 + cells) would represent ''MSCs'' (Caplan, 2008; Crisan et al., 2008) . Hence, these broadly multipotent progenitors, essentially defined by in vitro assays (Dominici et al., 2006; Pittenger et al., 1999) that are neither specific nor stringent, would be found in multiple tissues well beyond BM (e.g., skeletal muscle, fat, placenta, umbilical cord) (Caplan, 2008; da Silva Meirelles et al., 2006) . Definition of the origin, anatomy, biological properties, and function of so-called ''MSCs'' has obvious implications, both for understanding their biology and for their use in potential therapies. Notably, assuming that ''MSCs'' with identical differentiation properties can be isolated from virtually every tissue would imply that multiple tissues are equally suitable cell sources for the regeneration of multiple tissues. On the other hand, the assumption that ''MSCs'' are the ex vivo counterpart of pericytes would lend support to the view that a number of non-progenitor functions (Bianco et al., 2013) of ''MSCs'' (anti-inflammatory, immunomodulatory, trophic) , claimed to be of major import for therapy of a number of unrelated disorders (Caplan and Correa, 2011) , are traceable to an identifiable and ubiquitous in vivo cell type. Nonetheless, pericytes are only defined by anatomy, and currently no experimental data support the notion that they represent a distinct lineage (Armulik et al., 2011; Diaz-Flores et al., 2009 ). In addition, their role in tissue injury and repair is pleiotropic and spans multiple distinct processes including inflammation; furthermore, their participation in the repair of tissues (e.g., through the formation of scar tissue) does not necessarily coincide with a regenerative function.
We previously identified a minimal surface phenotype suited not only to enrich the archetypal human ''MSCs'' in uncultured BM cell suspensions, but also to correlate their ex vivo-assayed clonogenic capacity with their in situ identity and in vivo fate following transplantation . As applied to the study of BMSCs, this led to identification of ''MSCs'' as subendothelial, perivascular CD146 + cells on BM sinusoids, and also provided evidence for their self-renewal in vivo, which had long been the missing evidence to support the claim that BMSCs indeed include a subset of bona fide stem cells, rather than multipotent progenitors (Bianco et al., 2013; Sacchetti et al., 2007) . Using an identical approach to prospectively isolate ''MSCs'' from a variety of non-BM tissues, Crisan and co-workers later reported that a ubiquitous population of highly myogenic and skeletogenic CD146 + cells, coinciding with ''MSCs,'' is found in association with microvessels of skeletal muscle and other tissues, lending support to the view of pericytes as a uniform, widely distributed population of cells that can be explanted and cultured as ''MSCs'' (Caplan, 2008; Caplan and Correa, 2011; Crisan et al., 2008) . However, striated muscle and skeletal lineages such as bone, cartilage, and marrow fat diverge early in development, and no common progenitor of bone and muscle is found in prenatal life past the time of sclero-myotome specification in somites (Applebaum and Kalcheim, 2015) . The notion of a common postnatal progenitor of bone and muscle, therefore, would be at odds with established tenets in developmental biology (Bianco and Robey, 2015) . We show here that MCAM/CD146-expressing stromal cells from different human tissues diverge radically from their BM counterparts in differentiation potency and transcriptional profile, reflective of their different developmental origin. While BM-derived ''MSCs''/pericytes are natively skeletogenic but not myogenic, muscle-derived ''MSCs''/pericytes are inherently myogenic but not natively skeletogenic, and appear to represent a subset of cells with functional features of satellite cells, but not their characteristic anatomical location. We further show that prenatal, cord blood-borne ''MSCs'' in turn exhibit a distinct transcriptional and potency profile, and an inherent cartilage commitment, which diverge markedly from that of postnatal BM-derived ''MSCs.'' Finally we show that, irrespective of the postnatal tissue source of these perivascular cells or from fetal blood, these committed progenitors of mesoderm derivatives can associate with nascent blood vessels (BVs) in vivo and be recruited to a mural cell fate. However, a system of committed and self-renewing progenitors with distinct native potency, and not a uniform, equipotent class of ''MSCs'' is associated with microvascular walls in postnatal mesoderm-derived tissues as reported previously for bone/marrow , and as shown herein for muscle. Pericyte recruitment from preexisting local progenitors is a simple developmental process that explains the very existence of such progenitors in postnatal life and their tissue-specific properties.
RESULTS
The Phenotype of ''MSCs'' In Vitro Does Not Reflect Cell Identity and Function Stromal cell strains were established from four different tissue sources: BM, skeletal muscle (MU), periosteum (PE), and perinatal cord blood (CB). For all postnatal tissue sources, clonogenic cells were prospectively isolated based on a minimal surface phenotype as previously described for human BMSCs (CD34
À

/CD45
À /CD146 + ); colonies of CB stromal cells were established as described previously (Kluth et al., 2010; Kogler et al., 2004) . Of note, CD146 identified a clonogenic subset in MU (presented below) and PE (data not shown), as it does in BM. Multiclonal strains derived from growth of the originally explanted cells were then expanded under identical basal culture conditions that do not support the growth of endothelial cells or induce differentiation. All resulting cell strains exhibited the canonical in vitro cell-surface markers regarded as characteristic of ''MSCs'' ( Figure 1A ). To determine the specificity and functional significance of the cell-surface phenotype of ''MSCs,'' widely regarded as a defining feature of ''MSCs'' across tissues, we performed gene-expression profiling using Affimetrix technology. Both unsupervised hierarchical clustering ( Figure 1B ) and principal component analysis ( Figure 1C ) revealed that gene-expression profiles of ''MSCs'' are clearly separated by an ''origin'' factor, indicating the lack of specificity and sensitivity of the widely used ''minimum'' surface phenotype. ANOVA-based supervised analysis selected 1,614 class-specific, differentially expressed genes (Table  S1 ) showing a fold difference >3 and a false discovery rate q value of <0.05. While perinatal CB cells are characterized by over-representation of genes related to proliferation and cell-cycle regulation (Figures 2A-2C ), the postnatal MU cells are characterized by over-representation of tissue-specific genes related to their tissue origin ( Figures 2D and 2E ), including the myogenic transcription factor, PAX7 (Figure S1A) . Tables S2 and S3 show the first 100 enriched  gene sets for CB and MU classes, respectively, while Figures  2A1-2E1 show enrichment plots and heatmaps for selected gene sets. The over-represented gene sets coming from gene set enrichment analysis (GSEA) (Subramanian et al., 2005) support the notion that prospectively purified CB ''MSCs'' are highly proliferative, since the majority of gene sets enriched in this phenotype are related to proliferation, S phase, RNA and DNA synthesis, or DNA repair. On the other hand, prospectively purified MU ''MSCs'' are clearly characterized by the over-representation of gene sets specifically related to either muscle development or muscle differentiated function (muscle contraction, muscle development, and energy metabolism). PE and BM expression profiling was analyzed in the same way, but no gene sets were statistically significantly enriched in PE versus CB, BM, and MU, or in BM versus PE, CB, and MU. However, a number of genes enriched in BM and PE cells was identified (Table S4) . Furthermore, genes associated with hematopoietic support, a defining feature of BM cells, were over-represented in BM cells compared with CB, MU, and PE cells ( Figure S2A ). + and grown under basal conditions that do not induce differentiation, regularly form bone and establish the hematopoietic microenvironment when transplanted heterotopically using an osteoconductive carrier (Figure 3Aa ). Cells sorted based on the same phenotype from BM and other tissues, including MU, were later reported to be highly myogenic both in vitro + ''MSC'' strains were transplanted, using the same in vivo assay with hydroxyapatite/tricalcium phosphate (HA/TCP) as a scaffold (labeled s), osteogenic potential was restricted to BM-, PE-, and CB-derived cells. MU cells regularly failed to form any histologically identifiable bone.
(legend continued on next page) and in vivo, in addition to sharing the ability to differentiate in culture toward skeletal lineages (Crisan et al., 2008) , based on widely used artificial differentiation assays. In vitro, Alizarin red S and von Kossa staining cannot distinguish between dystrophic calcification induced by dead and dying cells versus matrix mineralization, or calcium phosphate precipitates generated by cleavage of b-glycerophosphate (a component of osteogenic medium) by alkaline phosphatase (ALP), which is expressed by many types of stromal cells. In vivo transplantation of MU ''MSCs'' of identical surface phenotype as BM ''MSCs'' revealed no spontaneous in vivo osteogenic potential ( Figure 3Ab ). Likewise, cells established in culture from skin, adipose tissue, and amniotic fluid, all sharing the in vitro phenotype of ''MSCs,'' regularly failed to form any histology-proven bone ( Figure S2 ), whereas PE ''MSCs'' did form bone in vivo, as previously reported Figure 3Ac ). Using the same in vivo assay and carrier, CB ''MSCs'' formed histology-proven bone of donor origin ( Figure 3Ad , human Lamin A/C-positive osteocytes, not shown). Surprisingly, they also generated Safranin O + , Alcian blue + , COL2 + hyaline cartilage intermingled with bone in the same assay (three of three strains from different donors, and one of three single colonyderived strain), but never established a hematopoietic microenvironment (Figures 3Ba-3Bh ). This result was unique, as previously we have never seen BM ''MSCs'' make cartilage in this ceramic-based assay. Failure to generate cartilage under these conditions has been interpreted as a need for a hypoxic environment for chondrogenesis in vivo, which is not provided in an open transplantation system permissive for vascularization. While hypoxia undoubtedly contributes to chondrogenesis (as in fracture callus formation; e.g., Hirao et al., 2006) , our results suggest that there are also cell-intrinsic factors at play in CB-derived chondrogenesis based on their more primordial, fetal origin (Bianco and Robey, 2015) . The myogenic capacity of the same cell strains was tested under stringent conditions (i.e., in the absence of exogenous myoblasts in vitro or endogenous myoblasts in vivo [Sherwood et al., 2004] , of demethylating agents such as 5-azacytidine [Wakitani et al., 1995] ). MU ''MSCs'' cultured without myoblasts in canonical myogenic conditions (2% horse serum on Matrigel) (Dellavalle et al., 2007) readily and efficiently generated myotubes in culture, whereas no myogenesis was observed under identical conditions with non-MU-derived stromal cells ( Figure 4A ). With these non-MU ''MSCs,'' myotubes could only be obtained in cocultures with myoblasts (mouse C2C12 cells). Notably, the vast majority of nuclei incorporated in the newly formed myotubes were murine, indicating that human non-MU ''MSCs'' contribute only marginally to myogenesis in vitro even in permissive co-culture differentiation assays (data not shown). In cultures of MU CD146 + cells ( Figure Tables S5A and S5B) , and expression of human muscle proteins in regenerating myofibers ( Figure 5C [CD56], Figure 5D [Dystrophin 2, Spectrin], and Table S5C ). Subsequently, enzyme-released cells of the harvested injected TA were used to perform secondary MU colony-forming efficiency (CFE) assays (Supplemental Experimental Procedures; Figure S3 ). Human cells were isolated based on hCD44, hCD90, and hCD146 expression and, after brief expansion (2 weeks), reanalyzed by fluorescence-activated cell sorting (FACS) for hCD44, hCD90, and hCD146 expression. The human cells were then isolated by MiniMacs (Miltenyi) and were replated in culture at clonal density. All colonies harvested at 2 weeks were uniformly positive for hCD146 and negative for hCD56 and hCD34, demonstrating that hCD146 + pericytes isolated from the injected muscle were the source of the secondary MU colonyforming unit-fibroblasts (CFU-Fs), indicative of self-renewal. The canonical in vivo muscle regeneration assay relies in large part on fusion between donor cells and host myoblasts, which implies recruitment of the former to a newly forming myotube where they will be reprogrammed by host myogenic factors. Even though CB, PE, and BM cells failed to differentiate under these conditions, a more stringent in vivo myogenesis assay requires the exclusion of such recruiting myoblasts. To this end, we suspended equal PE and CB ''MSCs'' formed bone, but never established a hematopoietic microenvironment. BM ''MSCs'' formed bone and established the hematopoietic microenvironment (asterisks in a, third panel), which is assessed by determining the presence of extravascular blood cells such as megakaryocytes and granulocytes, as seen under high-power microscopy (not shown). Scale bars represent 700 mm. (B) Clonal strains of CB CD146 + ''MSCs'' transplanted using HA/TCP as a scaffold (representative results from one of at least three transplants) generated abundant bone and hyaline cartilage (labeled c). a, b, f-h: Safranin O (stains chondrocytes and cartilage orange due to their proteoglycan content) and Fast green (stains bone matrix deep green-blue); c: H&E, whereby unlike bone which stains pink with eosin, cartilage stains light blue; d: Alcian blue (stains cartilage matrix); e: anti-type II collagen (an essential cartilage component) immunohistochemistry. Scale bars represent 700 mm (a), 150 mm (b-e), 40 mm (f), 15 mm (g), and 21 mm (h).
numbers of MU (transduced to express a cell-surface GFP label), BM, or CB cells with identical surface phenotype, grown in culture under identical basal conditions that did not induce differentiation, in growth factor-reduced Matrigel, and injected the resulting suspension into the epifascial space of the back of SCID/beige mice. Plugs harvested at 3 weeks demonstrated that MU cells had generated myotubes, myofibers, and a unique spheroidal syncytia expressing a differentiated muscle phenotype ( Figure 5E , desmin, MyHC, CD56). The myosac phenotype may result from spontaneous contraction of the myotube poorly adhering to the substrate and obviously not constrained by tendons. BM cells, while remaining viable, did not generate bone, cartilage, or muscle. CB cells, which formed bone and cartilage upon transplantation with an osteoconductive carrier, generated hyaline cartilage but not bone in Matrigel ( Figure 5F ).
MU CD146
+ Cells Are Perivascular, Committed
Myogenic Progenitors
These data revealed a strong, spontaneous myogenic capacity specific for MU CD146 + cells, fully consistent with the Figure 6C ). In situ, ALP and CD146 were expressed in a mutually exclusive fashion in precapillary arterioles and postcapillary venules, respectively, suggesting that the venous compartment represents the largest repository of perivascular CD146 + cells that can be assayed as myogenic progenitors ( Figure 6D ). Immunolocalization studies further revealed the presence of a relatively rare population of adventitial cells expressing muscle regulatory factor proteins (PAX3, PAX7) in postcapillary venules ( Figure 6E ). Freshly isolated MU CD146 + cells also co-expressed PAX7 by FACS ( Figure 6F ) and by RT-PCR ( Figure S1B ).
Generation of Perivascular Cells from Different Types of Stromal Cells In Vivo
In heterotopic transplants made with osteoconductive carriers, BM-derived skeletal stem cells can guide and organize the formation of BVs, with which a subset of them ultimately associates . To test the ability of BM-and non-BM-derived progenitors to guide and organize nascent BVs under simplified conditions that bar the formation of bone, we co-transplanted BM-and non-BMderived progenitors in Matrigel, along with human umbilical vein endothelial cells (HUVECs). With cell-surface GFP-labeled BM-derived progenitors, this resulted in the formation of an extensive network of capillary-like BVs at 3 weeks. Their wall was composed of two cell layers: an inner hCD34 + endothelial layer (red), and an outer, discontinuous layer of mural cells (green) made by transplanted BM progenitors, expressing CD146 and a-smooth muscle actin (a-SMA) ( Figure 7A ). In transplants harvested at 8 weeks, extensive maturation of the BV wall was observed, as indicated by the formation of thick-walled artery-and vein-like BVs, with a multilayered GFP + , a-SMA + smooth muscle coat. The BVs were functional and perfused by host blood ( Figure 7A ). Experiments performed with cellsurface GFP-labeled MU CD146 + cells also resulted in the formation of a capillary lattice, which was less extensive than with BM CD146 + cells, but similarly well organized ( Figure 7B , quantitated in Figure S5 + MU cells, transduced to express a cell-surface GFP label, were suspended in growth factor-reduced Matrigel (labeled matrigel in panels) without HUVECs and injected into the epifascial space of the back of SCID/beige mice, and harvested 3 weeks later. Extensive formation not only of myotubes (a, b, and h) expressing human-specific myogenic markers, Desmin (g and k), myosin heavy chain (MyHC, h and i), and CD56 (j), but even of striated myofibers (c-e, black arrows) and non-conventional muscle structures (f, red arrows, i-k) were observed (H&E, a-f). Scale bars represent 5 mm, 10 mm, 15 mm, 25 mm, or 50 mm as indicated. Figure 7C ), making these BVs a unique kind of cartilage-armored BV, not known to occur in natural tissues. Knockdown of CD146 in cell-surface GFP-labeled BM progenitors (as previously described by Sacchetti et al., 2007) (Supplemental Experimental Procedures) partially interfered with BV organization, resulting in BVs of irregular size and shape, often devoid of a lumen, and devoid of a mural cell coat ( Figure S6 ). Due to the ability of BM, MU, and CB cells to form perivascular cells, we examined the transcriptome data (including PE cells, although not used for this assay) for additional markers that are associated with pericytes (e.g., Armulik et al., 2011) . A variety of pericyte markers were expressed by all four cell populations, but the pattern of expression varied from one cell type to another, consistent with their diverse developmental origins ( Figure S7 ).
DISCUSSION
A widely accepted view in the literature holds that ''MSCs'' can be defined by rather loose and non-specific in vitro properties, and exhibit identical functional and differentiation properties regardless of their tissue source. This view, complemented by the notion that ''MSCs'' would coincide with ubiquitous pericytes, was recently reinforced by the claim that MU-derived pericytes would be both myogenic and skeletogenic, and exhibit an in situ surface phenotype similar to the one characteristic of BMSCs (i.e., of a skeletal stem cell origin) (Bianco, 2014 (Bianco and Robey, 2015) and are the only kind of human ''MSCs'' ever shown to actually form cartilage consistently in open heterotopic transplants in vivo, independent of any ex vivo induction to cartilage differentiation as applied in the widely used pellet culture assay. CB cells are unlike other cells that are found in the umbilical cord, based on their cell-surface markers, their ability to differentiate into adipocytes and cartilage, and expression of associated markers, and they have a distinct expression pattern of HOX genes compared with other umbilical cord derivatives (Bosch et al., 2012; Liedtke et al., 2010 Liedtke et al., , 2016 . BM-and MUderived clonogenic progenitors of mesoderm derivatives are associated with BV walls in situ and include cells in a position characteristic of mural cells/pericytes, but also include vascular-wall cells that do not necessarily exhibit anatomical features of pericytes proper, for example, adventitial cells in muscular veins. More strikingly, fetal chondro-osteoprogenitors that circulate in CB, by definition, are neither associated with BV walls nor represent pericytes. The origin of these cells remains to be elucidated. It is conceivable, however, that skeletal progenitors located at sites of active skeletal growth can accidentally spill over into the bloodstream. Nonetheless, independent of their origin, native differentiation potencies, gene-expression profiles, and in situ anatomical positioning, perinatal and postnatal mesoderm progenitors of different origins can dynamically associate with, and organize, nascent BVs as shown here using a simple in vivo assay.
Our data reveal that in lieu of a uniform, broadly multipotent, and equipotent class of ubiquitous ''MSCs,'' perinatal and postnatal assayable progenitors found in CB, skeletal tissues, and skeletal muscle comprise a varied system of tissue-specific progenitors. Each member of the system is committed to a specific differentiation range. CB mesenchymal progenitors are committed to cartilage and bone formation, reminiscent of the potential of prenatal skeletal progenitors to generate skeletal rudiments made of cartilage and bone. Postnatal BM skeletal progenitors are instead committed to bone and BM stroma formation, but not to cartilage, mirroring an adult structure of skeletal segments. Myogenic and skeletogenic potential are mutually exclusive, as dictated by a specific set of master transcriptional regulators.
Our data are consistent with recent studies showing that in vivo, transplants of BM cells were able to form bone and support marrow formation, while white adipose-derived stromal cells (WAT), cells from umbilical cord (UC), and skin fibroblasts (SF) were not (Kaltz et al., 2008; Reinisch et al., 2015) . Importantly, the ''MSCs'' derived from cord blood (CB) used in our study must be clearly distinguished from fibroblastic cells derived from UC ''MSCs'' in the Reinisch study; UC cells fail to differentiate in vitro and in vivo (Kaltz et al., 2008; Liedtke et al., 2016; Reinisch et al., 2015) , differ in their typical HOX expression pattern (Liedtke et al., 2010 (Liedtke et al., , 2016 , and have a different molecular transcriptomic signature lacking relevant integrin-binding sialoprotein (IBSP) expression (Bosch et al., 2012) . Differences in our study include culture in 20% fetal bovine serum (FBS) and use of a ceramic carrier that favors direct osteogenesis (no evidence of endochondral bone formation). In Reinisch et al. (2015) , BM cells were grown in 10% human platelet lysate and transplanted with a Matrigel equivalent (In Vitro Vasculogenesis Assay Kit; Millipore), and bone formed through an endochondral process. Another study investigated expression of mRNAs by BM cells, WAT cells, and CB cells at a multiclonal level (Ragni et al., 2013) . While the mRNA patterns between the cells types were similar, a small number of highly differentially expressed mRNAs were identified, which could affect the expression of many genes. Of note, in vitro osteogenic, adipogenic, and chondrogenic differentiation assays were performed in both of these studies, and significant differences were noted between the cell types. Nonetheless, the authors of both papers concluded that an in vitro mesengenic process was at play in all cell types. However, in vitro analyses of osteogenic differentiation are not predictive of in vivo transplantation (e.g., Phillips et al., 2014) . For chondrogenesis, 3D cultures are needed to clearly see bona fide chondrocytes lying in lacuna, surrounded by a matrix that stains purple with toluidine blue (metachromasia) as shown by Reinisch et al. (2015) . Close examination of this study suggests that there was little or no chondrogenic differentiation of WAT, UC, or SFs compared with BM cells. In Ragni et al. (2013) , chondrogenesis was difficult to assess based on Alcian blue-stained 2D cultures and expression of a limited number of markers, which is insufficient to confirm chondrogenic differentiation.
Even if updated to equate ''MSCs'' with pericytes (Caplan, 2008; Crisan et al., 2008) , the widespread concept of broadly and uniformly multipotent ''MSCs'' that are invariant in anatomical space and developmental time leaves the developmental origin of such cells unaddressed, and in fact collides with certain fundamental tenets of developmental biology, such as the early segregation of inherent osteogenic and myogenic potential into different lineages (Bianco and Robey, 2015) . Our data now reveal a simple mechanism whereby assayable skeletogenic or myogenic progenitors can be established in different tissues. As previously postulated (Bianco et al., 2008 (Bianco et al., , 2013 , we have now directly shown that committed progenitors of different origin and differentiation potential can physically associate with nascent BV walls in an experimental assay, and be recruited to a mural cell fate. In an earlier study, the most robust contribution of grafted mesoderm progenitor cells in quail chick chimeras was, in fact, to the adventitia of BVs of any caliber (Minasi et al., 2002) . In development, somite-derived cells associate with, and are incorporated into, the wall of the dorsal aorta (Esner et al., 2006) . Pericytes originate from the recruitment of non-endothelial, mesenchymal cells to vascular walls (Armulik et al., 2011; Hellstrom et al., 1999; Hirschi and D'Amore, 1996; Jain, 2003; Lindahl et al., 1997) . Obviously, the same mechanism may operate in different tissues and at different developmental times. General mechanisms regulating mural cell recruitment have largely been elucidated, and provide the background against which to seek additional determinants operating in the retention of quiescent mesoderm progenitors in a vascular niche. CD146 itself may represent a player in this scenario, consistent with its nature as a celladhesion molecule (Shih, 1999) , and with evidence provided here that its knockdown perturbs the establishment of properly structured BVs in vivo.
The direct interaction of committed progenitors with endothelial walls of nascent BV can be related to their arrested proliferation and differentiation, leading to retention, within specific tissues, of a compartment of progenitors with predefined commitment, and a potential for further growth defined by their replicative history prior to incorporation into BV walls. The long-known heterogeneity of clonogenic mesodermal progenitors (CFU-Fs) in proliferative potential ex vivo might find in this view a simple explanation.
Our data have additional implications of applied nature. Prospective isolation of putative ''MSCs'' from different tissues, based on the use of the minimal effective surface phenotype CD34
+ , leads to isolation of committed tissue-specific progenitors, not of broadly multipotent, equivalent cells. Hence, design of cell-therapy strategies for specific tissues must remain cognizant of the specificity of the isolatable progenitors. In fact, reliance on this specificity leads to highly effective isolation of tissue-specific progenitors. This is best illustrated by the case of skeletal muscle, where we have shown that CD146 + cells are far more enriched in spontaneously myogenic cells than previously identified populations of putative non-satellite cell classes (Dellavalle et al., 2007) . Importantly, we have shown that these cells, which do express the satellite lineage marker, PAX7, and behave like satellite cells in in vitro and in vivo assays (Montarras et al., 2005) , may in fact represent subsets of the same original population, recruited to distinct anatomical niches based on distinct, local cell-cell interactions, randomly directing individual progenitors to either the surface of developing fibers (satellite cells) or the surface of nascent BVs (myogenic pericytes, or else ectopic satellite cells). Consistent with this hypothesis, proximity of one anatomical locale to the other can amount, in fact, to less than one cell diameter. However, it is also possible that the pericytic MU CD146 + cells are more primitive than satellite cells based on the fact that they give rise to CD56 + satellite cells ( Figure 5C In summary, we have provided a rigorous analysis of mesodermal progenitors isolated from perinatal and postnatal tissues that reveals their inherent differentiation potential. These data underscore the fact that a ubiquitous ''MSC'' with identical differentiation capacities does not exist, and thus the ''MSC'' terminology should be abandoned for the sake of clarity. Furthermore, we have demonstrated that irrespective of their inherent differences, tissue-specific mesodermal progenitors are capable of being recruited to a mural cell fate, providing a plausible mechanism by which pericytes are formed, and how they serve as a source of local stem/progenitor cells. , and formation of discrete colonies was scored after 14 days. Non-clonal cultures were passaged when subconfluent; multiclonal cultures were passaged on day 14.
EXPERIMENTAL PROCEDURES
Cell Sorting and Flow Cytometry
Surface markers were assessed using a FACSCalibur flow cytometer with CellQuest software (BD Biosciences) as reported previously with mouse anti-human monoclonal antibodies (Table S7A) 
Gene-Expression Profiling and Data Analysis
Total RNA was isolated from multiclonal cultures of CD146 + cell populations from three independent cultures after 2 weeks of culture in basal medium (see above), and processed as described in Supplemental Experimental Procedures. Raw data of gene-expression profiling were submitted to the GEO repository (GEO: GSE69991).
Gene Set Enrichment Analysis
GSEA was performed using GSEA software (http://www. broadinstitute.org/gsea/index.jsp) (Subramanian et al., 2005) as described in Supplemental Experimental Procedures. 
Colony-Forming Efficiency Assays
In Vivo Transplantation Assays
All animal procedures were approved by the relevant institutional committees.
Heterotopic Bone Formation
Constructs of test cells and osteoconductive material (hydroxyapatite/tricalcium phosphate [HA/TCP; Zimmer]) were transplanted into the subcutaneous tissue of SCID/beige mice (CB17.CgPrkdc scid Lyst bg-J /Crl; Charles River), using an established assay (Krebsbach et al., 1997; Sacchetti et al., 2007) .
Orthotopic Myogenesis
CTX model: MU-BM-, and CB-derived cell populations (1 3 10 6 ) were injected intramuscularly into the left tibialis anterior of 2-month-old female SCID/beige mice injured 1 day earlier by an intramuscular injection of cardiotoxin (CTX; Latoxan) (Dellavalle et al., 2007) . Muscles were examined 4 weeks following transplantation. SCID/mdx model: MU-and BM-derived cell populations were injected via the femoral artery of 2-month-old female SCID/ mdx dystrophic mice (C57BL/10ScSn-mdx/J; Jackson Laboratory) as described by Dellavalle et al. (2007) . Two injections of 5 3 10 5 cells at a 15-day interval were performed, and animals were euthanized 15 days after the last injection (30 days in total). The injected tibialis anterior muscles were analyzed for myogenic markers by immunofluorescence, with uninjected contralateral muscles serving as controls.
Heterotopic Differentiation, Matrigel 1 3 10 6 cells from multiclonal cultures of MU, BM, and CB cells were suspended in 1 ml of Matrigel Growth Factor-Reduced (BD Biosciences Labware), either alone or mixed with an equal number of HUVECs (Cambrex). Aliquots ($0.7 ml) were injected in the subcutaneous tissue of the back of SCID/beige mice, and transplants were harvested after 20 days. In some experiments, cells from multiclonal cultures of MU and BM cells were transduced with GFP-lentiviral vectors.
Lentiviral Vectors
Lentiviral vectors for GFP expression and CD146 silencing were produced and used as described previously (Piersanti et al., 2010; Sacchetti et al., 2007) . Sorted CD146 + cells from BM and MU were transduced with GFP-lentiviral vectors at an MOI of 5 and cultured
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Immunohistochemistry Studies
Heterotopic and orthotopic transplants were processed as described in Supplemental Experimental Procedures. All experiments using mice were performed under institutionally approved protocols. All primary antibodies used for immunolocalization studies are listed in Table S7B .
RT-PCR
Conditions used in this study are described in Supplemental Experimental Procedures, and primers are listed in Table S7C . 
SUPPLEMENTAL INFORMATION
